Compare PWP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PWP | IVA |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | France |
| Employees | N/A | 84 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | N/A |
| Metric | PWP | IVA |
|---|---|---|
| Price | $17.23 | $6.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $23.50 | $15.91 |
| AVG Volume (30 Days) | ★ 745.3K | 256.4K |
| Earning Date | 05-01-2026 | 03-30-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 138.52 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.87 | N/A |
| Revenue Next Year | $17.04 | N/A |
| P/E Ratio | $36.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.44 | $2.70 |
| 52 Week High | $25.93 | $7.98 |
| Indicator | PWP | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 48.13 |
| Support Level | $17.05 | $5.79 |
| Resistance Level | $19.49 | $6.56 |
| Average True Range (ATR) | 0.76 | 0.28 |
| MACD | 0.13 | -0.04 |
| Stochastic Oscillator | 52.81 | 37.17 |
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.